Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyModa Health Cosentyx Prior Auth Policy Update | Op…
    Ask Trek AI about this page
    CurrentModa HealthPolicy M-0229

    Cosentyx (secukinumab) (Subcutaneous/Intravenous) — Prior Authorization and Medical Necessity

    Customize your policy alerts

    Sign up for Moda Health Policy M-0229 alerts

    Get alerted when Policy M-0229 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, dosing limits, initial and renewal authorization periods, and medical necessity criteria for Cosentyx (secukinumab) for Moda Health members across labeled indications. Applies to providers requesting coverage for subcutaneous and intravenous formulations.

    Policy Summary
    PayerModa Health
    PolicyCosentyx (secukinumab) (Subcutaneous/Intravenous) — Prior Authorization and Medical Necessity
    Policy CodePolicy M-0229
    Change TypeNo material changes
    Effective DateMay 5, 2026
    Last ReviewMay 5, 2026
    Next Review DateMay 5, 2026
    Key ActionSubmit prior authorization documenting age, baseline objective disease severity, required infection and vaccination screening, and required prior trial history per indication.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 moInitial PA validity
    12 moRenewal validity
    Some indicationsPrior trial reqs
    CRP/MRI

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    nr-axSpA objective inflammation
    MultipleCovered indications
    Indication-specificDosing regimens

    Coverage and Medical Necessity Criteria

    inv-01: Universal initial approval criteria

    Covered when ALL of the following are met

    Universal: Member is at least 18 years of age (unless otherwise specified); physician has assessed baseline disease severity using an objective measure/tool; member has been evaluated and screened for hepatitis B virus (HBV) prior to initiating treatment; provider confirms member is up to date with age‑appropriate vaccinations prior to initiating therapy; member has been evaluated and screened for latent tuberculosis (TB) prior to initiating treatment and will receive ongoing TB monitoring during treatment; provider confirms member will not receive live vaccines during therapy; member does not have an active infection (including clinically important localized infections); member is not on concurrent treatment with another biologic therapy or targeted synthetic therapy.

    Some indications specify different minimum ages; see indication-specific criteria.

    inv-02: Plaque Psoriasis (PsO) initial criteria

    Covered when ALL of the following are met

    Plaque Psoriasis: Member is at least 6 years of age; documented moderate to severe plaque psoriasis for at least 6 months with one of: involvement of ≥10% body surface area (BSA) OR Psoriasis Area and Severity Index (PASI) ≥10 OR incapacitating location/serious emotional consequences/intractable pruritus; AND member did not respond adequately (or is not a candidate) to a 4‑week minimum trial of topical agents AND a 3‑month minimum trial of at least one non‑biologic systemic agent AND a 3‑month minimum trial of phototherapy, unless member is already established on biologic/targeted synthetic therapy or has >10% BSA (in which case these trials are not required).

    Commercial and Medicaid step therapy requirements may further specify prior agents.

    inv-03: Adult Psoriatic Arthritis (PsA) initial criteria

    Covered when ALL of the following are met

    Adult PsA: Documented moderate to severe active psoriatic arthritis; for predominantly axial disease or enthesitis: failure of at least a 4‑week trial of one NSAID unless contraindicated; for peripheral arthritis or dactylitis: failure of at least a 3‑month trial of one conventional synthetic DMARD (e.g., methotrexate, azathioprine, sulfasalazine, leflunomide, hydroxychloroquine) unless contraindicated; OR member is already established on biologic or targeted synthetic therapy for PsA; may be used as single agent or with methotrexate; members new to subcutaneous Cosentyx must initiate at 150 mg before increasing to 300 mg unless coexistent plaque psoriasis.

    Commercial and Medicaid prior trial lists differ by payer.

    inv-04: Juvenile Psoriatic Arthritis (JPsA) initial criteria

    Covered when ALL of the following are met

    JPsA: Member is at least 2 years of age; documented moderate to severe active polyarticular juvenile psoriatic arthritis; may be used as single agent or with methotrexate; member has had at least a 1‑month trial and failure (unless contraindicated or intolerant) of prior therapy with either oral NSAIDs OR a conventional synthetic DMARD (e.g., methotrexate, leflunomide, sulfasalazine) OR member is already established on biologic/targeted synthetic therapy for JPsA.

    Commercial and Medicaid step therapy lists differ by age group.

    inv-05: Ankylosing Spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) initial criteria

    Covered when ALL required criteria are met

    Ankylosing Spondylitis (AS): Member is at least 12 years of age; documented active disease; AND member had an adequate trial and failure of at least TWO NSAIDs over a total of 4 weeks unless contraindicated; OR member is already established on biologic or targeted synthetic therapy for AS; note: members new to subcutaneous Cosentyx must initiate at 150 mg before increasing to 300 mg.
    nr-axSpA: Objective signs of inflammation (elevation of CRP above the upper limit of normal and/or sacroiliitis on MRI); member is without definitive radiographic evidence of sacroiliac joint structural damage; documented active disease; AND member had an adequate trial and failure of at least TWO NSAIDs unless contraindicated; OR member is already established on biologic or targeted synthetic therapy for nr‑axSpA.CRP > ULN or MRI sacroiliitis

    inv-06: Initial Therapy (selected indications)

    Covered when ALL of the following are met for the specified indication/population

    Medicaid - initial general trial requirement (some indications): Patient must try and have an inadequate response, contraindication, or intolerance to at least a 3‑month trial of ONE of: adalimumab (preferred agents noted), etanercept, OR Cosentyx SC; OR patient is continuing treatment.3 months
    Commercial - initial general trial requirement: Patient must try and have an inadequate response, contraindication, or intolerance to at least a 3‑month trial of Cosentyx SC or Rinvoq (upadacitinib); OR patient is continuing treatment.3 months
    Medicaid - alternative statement: For some Medicaid indications patient must try and have an inadequate response, contraindication, or intolerance to at least a 3‑month trial of Cosentyx SC; OR patient is continuing treatment.3 months

    inv-07: Non-Radiographic Axial Spondyloarthritis (nr-axSpA) Initial Criteria

    Covered when ALL of the following are met for non-radiographic axial spondyloarthritis (nr-axSpA):

    Objective inflammation: Member has objective signs of inflammation evidenced by elevation of C‑reactive protein (CRP) above the upper limit of normal and/or sacroiliitis on magnetic resonance imaging (MRI).
    No definitive radiographic evidence: Member is without definitive radiographic evidence of structural damage on the sacroiliac joints.
    Documented active disease.
    Prior NSAID or established biologic: Member had adequate trial and failure of at least TWO NSAIDs unless contraindicated; OR member is already established on biologic or targeted synthetic therapy for nr‑axSpA.

    inv-08: Renewal / Continuation Therapy

    Renewal is allowed when ALL of the following are met:

    Continued indication-specific criteria: Member continues to meet the universal and other indication‑specific relevant criteria identified in section III.
    Absence of unacceptable toxicity from the drug (examples include severe new or worsening inflammatory bowel disease, severe infections including TB or HBV reactivation, severe hypersensitivity reactions such as anaphylaxis, urticaria, angioedema).
    Demonstrated disease response: Documented disease response compared with baseline using indication‑specific metrics (examples: PASI/BSA for psoriasis; joint counts, CRP, imaging or composite scores for PsA; ASDAS/BASDAI for AS and nr‑axSpA; HiSCR for HS; JADAS/ACR‑Pedi for pediatric arthritis).
    Dose escalation allowed: For adults (selected indications), dose escalation up to maximum dose/frequency may occur on clinical review if initial improvement was shown and there was loss of response or continued active disease, provided loading/maintenance dosing criteria were met as detailed in dosing section.

    inv-09: Dosing / Administration per Indication

    Dosing recommendations provided in the policy for specific indications and populations

    Non-radiographic Axial Spondyloarthritis (nr-axSpA): Subcutaneous: 150 mg SC every 4 weeks, with or without a loading dose. Intravenous: with loading dose 6 mg/kg IV at Week 0 followed by 1.75 mg/kg every 4 weeks; without loading dose 1.75 mg/kg IV every 4 weeks.

    Cosentyx may be administered with or without a loading dose for this indication.

    Enthesitis‑Related Arthritis (ERA): Pediatric dosing: weight ≥15 kg and <50 kg: 75 mg SC at Weeks 0,1,2,3,4 then every 4 weeks; weight ≥50 kg: 150 mg SC at Weeks 0,1,2,3,4 then every 4 weeks. Note: only subcutaneously administered products may be used for this indication; pediatric members should not self‑administer (adult caregiver to prepare and inject after training).
    Adult psoriasis (example): Adults: 300 mg SC at Weeks 0,1,2,3,4 followed by 300 mg every 4 weeks. Each 300 mg dose may be given as one 300 mg injection or two 150 mg injections.
    Hidradenitis Suppurativa (HS):

    Concurrent use of Cosentyx with another biologic agent or a targeted synthetic therapy is not permitted. Prior to authorization, the provider must confirm the member is not on concurrent treatment with another biologic therapy or targeted synthetic therapy, and requests may be denied if concurrent biologic/targeted synthetic therapy is documented.

    Coverage is excluded when objective criteria required for a specific diagnosis are not met or when the member demonstrates unacceptable toxicity from the drug at renewal. For example, non-radiographic axial spondyloarthritis requires documented objective inflammation (elevated CRP and/or MRI sacroiliitis) and absence of definitive radiographic sacroiliac damage; absence of these objective findings would preclude coverage. At renewal, ongoing authorization requires absence of unacceptable toxicity (see renewal criteria) and lack of required objective findings or evidence of drug-related unacceptable toxicity may result in denial.

    Certain pediatric indications are limited to subcutaneous (SC) formulations only. For Enthesitis‑Related Arthritis (ERA) and pediatric psoriasis/ERA dosing, the policy specifies weight-based SC dosing and states: Only the subcutaneously administered products may be used for this indication. The IV formulation (vial) is indicated for intravenous use in adults only and IV infusion must be performed by a healthcare professional in a healthcare setting.

    Medicare Part B covered diagnosis codes are not provided in this excerpt. The policy notes Medicare Part B Covered Diagnosis Codes: N/A for the portion of the document shown and directs consultation of applicable NCD/LCD/LCA guidance where relevant.

    Use of Cosentyx is contraindicated when the member has an active infection or has not completed recommended infection screening. Providers must document latent TB and HBV screening prior to initiation and confirm the member will not receive live vaccines during therapy. Requests may be denied if there is an active infection, missing TB/HBV screening, ongoing live vaccination, or other infection‑related safety concerns.

    Renewal will not be supported if there is evidence of unacceptable toxicity attributable to Cosentyx. Examples provided include severe exacerbation or new onset inflammatory bowel disease (IBD), severe infections (e.g., TB, serious bacterial, viral, or fungal infections, HBV reactivation), and severe hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria). Documentation of such events should be included with renewal requests and may be grounds for therapy discontinuation.

    Operational limits for pediatric administration: pediatric members should not self-administer; an adult caregiver must prepare and inject Cosentyx after appropriate training in subcutaneous injection technique. Additionally, intravenous infusion is limited to healthcare professional administration in a healthcare setting (i.e., IV is not for pediatric self‑administration).

    Coding, Dosing Units, and Key Clinical Thresholds

    Dosing/HCPCS units (descriptive)HCPCS
    HCPCS unitMax units specified per dose and over time by indication and route (examples: 150 mg, 300 mg SC dosing; IV loading 750 billable units; IV maintenance 375 billable units).
    HCPCS CodesHCPCS
    J3247Injection, secukinumab, intravenous, 1 mg; 1 billable unit = 1 mg (IV formulation ONLY)
    J3590Unclassified biologics (SQ formulation ONLY)
    C9399Unclassified drugs or biologicals (SQ formulation ONLY)
    NDC / Product presentation (partial list)NDC
    00078-1070-xxCosentyx 300 mg/2 mL UnoReady pen or prefilled syringe (subcutaneous)
    00078-0639-xxCosentyx 150 mg/mL Sensoready pen or prefilled syringe (subcutaneous)
    00078-1056-xxCosentyx 75 mg/0.5 mL prefilled syringe (pediatric <50 kg; subcutaneous)
    00078-1168-xxCosentyx 125 mg/5 mL single-dose vial for dilution prior to intravenous injection (IV)
    Covered ICD-10 Codes — SubcutaneousICD-10Covered
    L40.0Psoriasis vulgaris
    L40.50Arthropathic psoriasis, unspecified
    L40.51Distal interphalangeal psoriatic arthropathy
    L40.52Psoriatic arthritis mutilans
    L40.53Psoriatic spondylitis
    L40.54Psoriatic juvenile arthropathy
    L40.59Other psoriatic arthropathy
    L73.2Hidradenitis suppurativa
    M08.80Other juvenile arthritis, unspecified site
    M08.811Other juvenile arthritis, right shoulder
    1–10 of 76
    1/8
    Covered ICD-10 Codes — IntravenousICD-10Covered
    L40.50Arthropathic psoriasis, unspecified
    L40.51Distal interphalangeal psoriatic arthropathy
    L40.52Psoriatic arthritis mutilans
    L40.53Psoriatic spondylitis
    L40.54Psoriatic juvenile arthropathy
    L40.59Other psoriatic arthropathy
    M45.0Ankylosing spondylitis of multiple sites in spine
    M45.1Ankylosing spondylitis of occipito-atlanto-axial region
    M45.2Ankylosing spondylitis of cervical region
    M45.3Ankylosing spondylitis of cervicothoracic region
    1–10 of 26
    1/3
    Plaque Psoriasis severity thresholds
    Plaque psoriasis severity thresholdInvolvement of at least 10% body surface area (BSA) OR PASI score ≥10 OR incapacitating/critical location or serious emotional consequences/ intractable pruritus
    Minimum disease durationDocumented moderate to severe plaque psoriasis for at least 6 months
    Prior topical/systemic/phototherapy trialsFailure or not a candidate for 4-week topical trial, 3-month non-biologic systemic agent trial, and 3-month phototherapy trial (waived if already on biologic/targeted therapy or >10% BSA)
    Objective inflammation for nr-axSpA
    Objective inflammation requirement for nr-axSpAElevation of C‑reactive protein (CRP) above the laboratory upper limit of normal and/or sacroiliitis demonstrated on MRI

    Prior Authorization, Documentation, and Step Therapy Requirements

    Prior Authorization

    Prior authorization validity and required submission data

    Initial prior authorization is valid for 6 months (180 days); renewals may be requested every 12 months (365 days). Submission must document member age and baseline disease severity assessment plus required infection and vaccination screening prior to initiation.

    • Initial PA: 6 months (180 days)
    • Renewal interval: every 12 months (365 days)
    • Include age and baseline objective severity assessment
    • Document HBV screening, TB screening, and up-to-date vaccinations
    Prior Authorization

    Prior authorization required for initial therapy — document prior trials or continuation

    Prior authorization is required for initiation unless the patient is already established on biologic/targeted therapy; PA requests must document required prior trials or meet indication-specific continuation rules (examples vary by payer and indication).

    Drug Background and Clinical Context

    Secukinumab (Cosentyx) is an interleukin‑17A (IL‑17A) inhibitor indicated for multiple immune‑mediated conditions including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non‑radiographic axial spondyloarthritis, juvenile psoriatic arthritis, and hidradenitis suppurativa. The policy frames clinical coverage around age thresholds, objective disease measures, infection and vaccination screening, and formulation‑specific dosing and route restrictions to support safe and appropriate use.

    Definitions and Clinical Measurement Key

    Objective disease measures
    Body Surface Area (BSA)Percent of body surface involved in psoriasis (policy uses BSA ≥10% as a threshold for moderate–severe disease)
    Psoriasis Area and Severity Index (PASI)PASI score; policy cites PASI ≥10 as threshold for moderate–severe plaque psoriasis
    C‑reactive protein (CRP)CRP elevation above the upper limit of normal used to document objective inflammation (e.g., nr‑axSpA criteria and arthritis response measures)
    MRI evidence of sacroiliitisMRI demonstration of sacroiliitis used to document objective inflammation in nr‑axSpA
    Disease response
    Psoriasis response metricsImprovement measured by PASI or BSA (examples include achieving PASI ≤3 or BSA ≤1% referenced as disease response targets)

    Policy Revision History

    2015-02-24origin

    Policy originated (Date of Origin).

    2015-02review

    Initial review listed in policy history (Dates Reviewed includes 02/2015).

    2016-01review

    Policy reviewed (Dates Reviewed includes 01/2016).

    Policy Summary
    PayerModa Health
    PolicyCosentyx (secukinumab) (Subcutaneous/Intravenous) — Prior Authorization and Medical Necessity
    Policy CodePolicy M-0229
    Change TypeNo material changes
    Effective DateMay 5, 2026
    Last ReviewMay 5, 2026
    Next Review DateMay 5, 2026
    Key ActionSubmit prior authorization documenting age, baseline objective disease severity, required infection and vaccination screening, and required prior trial history per indication.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaCoding, Dosing Units, and Key Clinical ThresholdsPrior Authorization, Documentation, and Step Therapy RequirementsDrug Background and Clinical ContextDefinitions and Clinical Measurement KeyPolicy Revision History
    Enthesitis‑Related Arthritis (ERA) initial criteria: Member is 4 to <18 years of age; documented moderate to severe active polyarticular disease; trial and failure of at least 1 month of NSAID OR csDMARD unless contraindicated/intolerant OR already established on biologic/targeted therapy; AND trial of a 3‑month Cosentyx SC unless continuing treatment.
    Hidradenitis Suppurativa (HS) initial criteria: Member is at least 12 years of age; moderate to severe disease with ≥5 inflammatory lesions across ≥2 distinct anatomic areas; AND inadequate response/contraindication/intolerance to at least a 3‑month trial of ONE of: adalimumab or Cosentyx SC; OR patient is continuing treatment.
    Dose frequency every 4 weeks; if inadequate response, increasing to 300 mg every 2 weeks may be considered.

    Specific escalation criteria referenced in renewal section.

    Radiographic exclusionMember must be without definitive radiographic evidence of structural sacroiliac joint damage
    Documented active diseaseEvidence of active disease required in addition to objective inflammation
    Pediatric weight thresholds for dosing
    Pediatric weight band — small children≥15 kg and <50 kg (e.g., ERA dosing: 75 mg SC at Weeks 0–4 then every 4 weeks)
    Pediatric weight band — ≥50 kg≥50 kg (e.g., ERA dosing: 150 mg SC at Weeks 0–4 then every 4 weeks)
    Adolescent dosing bandsWeight ≥30 kg and <90 kg: 150 mg SC at Weeks 0–4 then every 4 weeks; Weight ≥90 kg: 300 mg SC at Weeks 0–4 then every 4 weeks
  1. Document prior trial(s) or state patient is continuing therapy per indication-specific rules
  2. Examples include payer-specific trial lists (e.g., adalimumab, etanercept, Cosentyx SC, Rinvoq)
  3. If already established on biologic/targeted therapy, prior-trial requirements may be waived
  4. Prior Authorization

    PA consideration and affected billing codes

    PA may be applied to Cosentyx based on the utilization management NQTL assessment; billable HCPCS codes for IV and SQ formulations are listed and may be used to identify affected claims.

    • NQTL checklist was used when designing PA (includes cost, indication, safety)
    • Affected HCPCS codes include J3247 and general drug coding (see HCPCS table)
    Prior Authorization

    Prior authorization may be applied (NQTL basis)

    The NQTL checklist indicates prior authorization may be applied to this drug group — factors considered include indication, safety/efficacy, misuse potential, medical necessity, and cost.

    • Appendix A NQTL Factor Checklist informed PA design
    • Cost was specifically noted as a reason to consider PA
    Step Therapy

    Step therapy — document prior biologic/alternative agent trial and outcome

    Many indications require a prior trial and inadequate response, intolerance, or contraindication to specified biologic or alternative agents; PA must include documentation of trial duration and outcome or reason for exemption.

    • Commercial and Medicaid lists differ — include exact agent tried (e.g., adalimumab, etanercept, Cosentyx SC, Rinvoq)
    • Document trial duration (commonly ≥3 months where specified) and inadequate response/intolerance/contraindication
    • Pediatric-specific prior‑trial lists exist for age-based groups
    Step Therapy

    Step therapy requirements — document agent, duration, and outcome

    Step therapy requirements commonly mandate inadequate response, intolerance, or contraindication to specified first-line agents before Cosentyx is authorized; include payer- and indication-specific agent names and trial durations in the PA request.

    • Examples: 3-month trial of listed alternatives for Commercial/Medicaid where specified
    • For ERA and HS, specified alternative trials (NSAID/csDMARD or adalimumab/Cosentyx SC) are required unless already on biologic therapy
    Step Therapy

    Step therapy sequence not specified in excerpt — use indication/payer lists

    The provided excerpt does not specify a uniform step-sequence for all indications; the NQTL appendix notes PA methods were considered but specific step-therapy sequences are not detailed here.

    • If sequence is required by payer, use the indication-specific lists in sections for Commercial vs Medicaid
    • When sequence is unclear, document the exact prior agents tried and rationale for selection
    Documentation Required

    Required baseline documentation before starting therapy

    Prior to initiation, providers must document baseline disease severity using an objective measure/tool, screen for HBV, confirm up-to-date vaccinations, screen for latent TB with plan for ongoing TB monitoring, and confirm absence of active infection and no concurrent biologic/targeted synthetic therapy.

    • Baseline objective disease severity assessment (e.g., BSA, PASI, joint counts, CRP, ASDAS/BASDAI as applicable)
    • HBV screening prior to treatment
    • Confirm member is up to date with age-appropriate vaccinations and will not receive live vaccines during therapy
    • Latent TB screening prior to initiation and plan for ongoing TB monitoring
    • Confirm no active infection and no concurrent biologic/targeted synthetic therapy
    Documentation Required

    nr‑axSpA — document objective inflammation and imaging

    For nr-axSpA PA requests, document objective signs of inflammation (elevated CRP above ULN and/or sacroiliitis on MRI), absence of definitive radiographic sacroiliac joint structural damage, documented active disease, and prior NSAID trial history or established biologic therapy status.

    • CRP above upper limit of normal and/or MRI evidence of sacroiliitis
    • No definitive radiographic sacroiliac structural damage documented
    • Documented active disease
    • Adequate trial and failure of at least two NSAIDs unless contraindicated, or documentation that member is established on biologic/targeted therapy
    Documentation Required

    Renewal documentation — continued criteria, response, and safety

    For renewal requests document that the member continues to meet universal and indication‑specific criteria, demonstrate disease response with appropriate measures, and confirm absence of unacceptable toxicity (examples: severe/new IBD, serious infections, HBV reactivation, hypersensitivity).

    • Evidence of disease response (e.g., PASI/BSA for PsO; joint counts/CRP/imaging for PsA; ASDAS/BASDAI or ASAS40 for axial disease; HiSCR for HS; JADAS/ACR‑Pedi for pediatric arthritis)
    • Statement that member continues to meet universal and indication‑specific criteria
    • Document absence of unacceptable toxicity or adverse events listed
    Documentation Required

    Document product, route, dose, and pediatric weight

    Document the specific product formulation (NDC), route of administration (subcutaneous vs intravenous), exact dose, and for pediatric patients include current patient weight to support the dosing selected.

    • Include NDC/product presentation (e.g., 00078-1070-xx, 00078-0639-xx, 00078-1056-xx, 00078-1168-xx)
    • Specify route: SC vs IV and that IV vial is for adult IV use only
    • Record exact dose and dosing schedule being requested
    • For pediatric dosing, include patient weight category to match dosing guidance
    Note

    Medicare Part B documentation note — consult NCD/LCD/LCA

    Consult CMS NCD/LCD/LCA guidance for Medicare Part B applicability where relevant; documentation and coverage must comply with any applicable NCD/LCD/LCA requirements referenced by CMS.

    • Medicare coverage and Part B rules may apply to outpatient drugs — check NCD/LCD/LCA guidance
    • Policy notes N/A for Medicare Part B Covered Diagnosis Codes in this excerpt but CMS documents may still be relevant
    Denial Risk

    Denial risk — age and baseline assessment missing or below minimum

    PA requests may be denied if the member is below the minimum age specified for the indication or if baseline disease severity has not been assessed and documented with an objective measure.

    • Confirm member meets indication‑specific minimum age (policy lists ages per indication)
    • Provide baseline objective severity assessment (e.g., BSA, PASI, joint counts, CRP) to avoid denial
    Denial Risk

    Denial risk — infection, screening, and concurrent therapy exclusions

    PA may be denied for active infection, missing TB/HBV screening, use of live vaccines during therapy, or concurrent treatment with another biologic/targeted synthetic therapy; confirm these exclusions before submission.

    • No active infection present
    • Latent TB screening completed and plan for ongoing monitoring
    • HBV screening completed prior to treatment
    • Member will not receive live vaccines during therapy
    • No concurrent biologic or targeted synthetic therapy
    Denial Risk

    Denial risk — missing prior‑trial documentation

    Requests can be denied if required prior trials (including duration and outcome) of specified agents are not documented; include documentation of inadequate response, intolerance, or contraindication to the named prior agents per payer and indication.

    • Document agent(s) tried (e.g., adalimumab, etanercept, Cosentyx SC, Rinvoq)
    • Document trial duration (commonly 3 months where specified) and outcome (inadequate response/intolerance/contraindication)
    • If exempted, document reason (e.g., already established on biologic, contraindication)
    Prior Authorization

    PA consideration for cost — ensure full clinical justification

    PA may be applied in part because of drug cost; include complete clinical justification and meet NQTL-based documentation expectations to support medical necessity.

    • Appendix A notes cost as a factor to consider for PA
    • Provide clear clinical rationale and required objective measures to address utilization management concerns
    Note

    Prior authorization considerations (NQTL) — factors reviewed

    When submitting PA, be prepared for NQTL-based review: the checklist considered indication, safety/efficacy, potential for misuse, medical necessity, and cost when designing PA requirements.

    • NQTL factors reviewed: indication, safety/efficacy, misuse potential, medical necessity, and cost
    • Expect PA review to reflect these considerations
    Note

    Operational NQTL/PA note — follow indication‑specific lists

    Operational note: NQTL/PA methods are referenced in the Appendix but additional operational details (e.g., step sequences) are not included in this excerpt; follow payer-specific prior‑therapy lists in the indication sections when completing PA submissions.

    • Appendix A references NQTLs and PA methods
    • Use the Commercial vs Medicaid prior‑trial lists in the indication sections for operational step requirements
    Arthritis response metricsImprovement in tender/swollen joint counts, CRP reduction, patient global assessment, or composite scores (e.g., JADAS, ACR‑Pedi) for pediatric arthritis
    Axial disease response metricsImprovements in total back pain, physical function, CRP, or disease activity scores (e.g., ASDAS ≥1.1 improvement, BASDAI ≥2, or ASAS40 response)
    Hidradenitis suppurativa responseHiSCR: ≥50% reduction in abscess and inflammatory nodule count with no increase in abscesses/draining fistulas
    Cosentyx SC
    Cosentyx SC definitionSelf‑administered subcutaneous formulation of secukinumab (UnoReady/Sensoready pens and prefilled syringes)
    Typical SC presentationsIncluded product presentations: 300 mg/2 mL (UnoReady) and 150 mg Sensoready pen/prefilled syringe noted in policy NDC listings
    Use constraintsSC products are for subcutaneous use only; pediatric and adult indications specify when SC is the required route
    Loading dose
    Loading dose definitionAn initial dosing regimen given at treatment start (policy notes Cosentyx may be administered with or without a loading dose for certain indications)
    Example — IV loading for nr‑axSpAIV with loading dose: 6 mg/kg IV at Week 0 followed by 1.75 mg/kg every 4 weeks thereafter
    SC loading practice noteSome indications list initial weekly SC dosing at Weeks 0–4 as the loading series prior to maintenance dosing every 4 weeks
    Subcutaneous versus Intravenous formulations
    Route/formulation distinctionSubcutaneous pens and prefilled syringes are for subcutaneous use only; solution in vials is for intravenous use in adults only
    Age and route constraintsPediatric indications require subcutaneous products only (e.g., ERA, pediatric psoriasis); IV solution is limited to adult use and must be administered by a healthcare professional in a healthcare setting
    Self‑administration guidanceAdult members may self‑administer SC Cosentyx or receive injection from a trained caregiver; pediatric members should not self‑administer—an adult caregiver must prepare and inject after training
    2017-01review

    Policy reviewed (Dates Reviewed includes 01/2017).

    2018-01review

    Policy reviewed (Dates Reviewed includes 01/2018).

    2018-08review

    Policy reviewed (Dates Reviewed includes 08/2018).

    2019-08review

    Policy reviewed (Dates Reviewed includes 08/2019).

    2020-03review

    Policy reviewed (Dates Reviewed includes 03/2020).

    2020-07review

    Policy reviewed (Dates Reviewed includes 07/2020).

    2021-07review

    Policy reviewed (Dates Reviewed includes 07/2021).

    2021-08review

    Policy reviewed (Dates Reviewed includes 08/2021).

    2022-01review

    Policy reviewed (Dates Reviewed includes 01/2022).

    2022-08review

    Policy reviewed (Dates Reviewed includes 08/2022).

    2023-06review

    Policy reviewed (Dates Reviewed includes 06/2023).

    2023-08review

    Policy reviewed (Dates Reviewed includes 08/2023).

    2023-11review

    Policy reviewed (Dates Reviewed includes 11/2023).

    2023-12review

    Policy reviewed (Dates Reviewed includes 12/2023).

    2024-08review

    Policy reviewed (Dates Reviewed includes 08/2024).

    2025-03review

    Policy reviewed (Dates Reviewed includes 03/2025).

    2026-03review

    Policy reviewed (Dates Reviewed includes 03/2026).

    2026-04review

    Policy reviewed (Dates Reviewed includes 04/2026).

    2026-05-05effective_and_reviewLatest

    Policy effective and last reviewed on 2026-05-05; next review noted as 2026-05-05 in policy metadata.